ImmunoGen, Inc. Announces Clinical Presentations at the ASCO 2011 Annual Meeting
26 May 2011 - 8:30PM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
biotechnology company that develops targeted antibody-based
anticancer products using its antibody expertise and Targeted
Antibody Payload (TAP) technology, today announced that favorable
clinical data on two ImmunoGen-created TAP compounds – IMGN901 and
SAR3419 – are being presented at the ASCO 2011 Annual Meeting
taking place in Chicago, IL, June 4-8, 2011.
“Our TAP technology has an unmatched level of reported clinical
data, and this body of data will expand meaningfully at ASCO this
year,” said Daniel Junius, President and CEO. “On June 4th, the
first clinical data for SAR3419 dosed weekly will be reported. We
believe these data will provide insight into Sanofi’s interest in
advancing SAR3419 into Phase II testing later this year. Then, on
June 5th, there will be an oral presentation featuring interim
findings with our IMGN901 compound used in a combination regimen to
treat multiple myeloma. The tolerability profile of IMGN901, and
other TAP compounds, supports assessment as part of combination
regimens, which we believe is an important development path for
IMGN901.”
Saturday, June 4 – SAR3419 poster presentation with oral
discussion
“Phase I/II study of the anti-CD19 maytansinoid immunoconjugate
SAR3419 administered weekly to patients (pts) with
relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL).” (abstract
#8017):
- Poster presentation: 8:00 am-12:00 noon
CT, room E450b, Poster 3
- Oral discussion session: 12:00
noon-1:00 pm CT, room E354a
SAR3419 is a potential new targeted therapeutic for the
treatment of B-cell NHL. It was developed initially by the Company
and licensed to Sanofi from ImmunoGen’s preclinical pipeline as
part of a broader collaboration.
Sunday, June 5 – IMGN901 oral presentation
“Phase I study of lorvotuzumab mertansine (LM, IMGN901) in
combination with lenalidomide (Len) and dexamethasone (Dex) in
patients with CD56-positive relapsed or relapsed/refractory
multiple myeloma (MM).”(abstract #8013):
- Oral presentation: 11:30-11:45 am CT,
room E354a
IMGN901 was developed by ImmunoGen and is wholly owned by the
Company. It is a potential new targeted therapeutic for the
treatment of small-cell lung cancer, Merkel cell carcinoma, ovarian
cancer, multiple myeloma and other CD56-expressing cancers.
Other Presentations
Other presentations at ASCO on compounds in development using
ImmunoGen’s TAP technology include two poster presentations in the
Trials in Progress Poster session related to the design of the
MARIANNE and EMILIA trastuzumab emtansine (T-DM1) Phase III
clinical trials (abstracts #TPS102 and #TPS116, respectively).
Trials in Progress abstracts and presentations are prohibited from
including clinical findings.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using
the Company's expertise in tumor biology, monoclonal antibodies,
potent cancer-cell killing agents and engineered linkers. The
Company's TAP technology uses monoclonal antibodies to deliver one
of ImmunoGen's proprietary cancer-cell killing agents specifically
to tumor cells. There are currently six TAP compounds in the
clinic, with a wealth of clinical data reported with the
technology. ImmunoGen’s collaborative partners include Amgen, Bayer
HealthCare Pharmaceuticals, Biotest, Genentech (a member of the
Roche Group), Novartis, and Sanofi. The most advanced compound
using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is
in Phase III testing through the Company's collaboration with
Genentech. More information about ImmunoGen can be found at
www.immunogen.com.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including IMGN901 and SAR3419, including
risks related to uncertainties around preclinical studies,
regulatory submissions and reviews, and their timings and results.
A review of these risks can be found in ImmunoGen’s Annual Report
on Form 10-K for the fiscal year ended June 30, 2010 and other
reports filed with the Securities and Exchange Commission.
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024